Lanreotide Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 60 mg, 90 mg, 120 mg
Reference Brands: omatuline Depot (USA), Somatuline Autogel (USA)
Category:
Oncology Cancer Care
Lanreotide is a synthetic octapeptide analogue of somatostatin. It binds to somatostatin receptors (SSTR‑2 and SSTR‑5), inhibiting secretion of growth hormone and other hormones. It is used to treat Acromegaly when surgery/radiotherapy are not suitable and to manage certain neuroendocrine tumours, including gastrointestinal/pancreatic NETs and symptoms of Carcinoid syndrome.
Lanreotide is available in Injection
and strengths such as 60 mg, 90 mg, 120 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lanreotide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lanreotide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lanreotide acetate is a long-acting somatostatin analogue used in the management of hormonal disorders and certain neuroendocrine tumors. It is primarily indicated for the treatment of acromegaly caused by growth hormone–secreting tumors of the pituitary or non-pituitary origin. By mimicking the natural hormone somatostatin, lanreotide helps reduce the secretion of growth hormone and insulin-like growth factor-1 (IGF-1), thereby controlling disease symptoms and biochemical markers. It is also used to manage symptoms associated with neuroendocrine tumors, particularly carcinoid tumors and VIPomas, where it helps control hormone-related effects such as flushing and diarrhea. In some regions such as the United Kingdom, it is additionally indicated for thyrotrophic adenoma (TSH-secreting pituitary tumors). Lanreotide is administered as a prolonged-release deep subcutaneous injection, allowing sustained therapeutic levels with extended dosing intervals. The product is widely marketed under the brand name Somatuline and is manufactured by Ipsen. It is approved and available in multiple international markets including the United States, United Kingdom, Canada, and Australia for specialized endocrine and oncology use.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing